TW201734035A

TW201734035A - 胜肽類似物

胜肽類似物 Download PDF

Info

Publication number: TW201734035A
Authority: TW; Taiwan
Prior art keywords: group; acy; acid; empty; gly
Prior art date: 2016-01-04

Application number

TW106100180A

Other languages

English (en)

Chinese (zh)

Inventor

曉瑜許

Original Assignee

艾得珮索拉公司

Priority date

2016-01-04

Filing date

2017-01-04

Publication date

2017-10-01

2017-01-04 Application filed by 艾得珮索拉公司 filed Critical 艾得珮索拉公司

2017-10-01 Publication of TW201734035A publication Critical patent/TW201734035A/zh

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 337
239000005557 antagonist Substances 0.000 claims abstract description 115
230000002483 superagonistic effect Effects 0.000 claims abstract description 77
239000000556 agonist Substances 0.000 claims abstract description 61
-1 superagonist Substances 0.000 claims abstract description 33
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 111
235000001014 amino acid Nutrition 0.000 claims description 95
229940024606 amino acid Drugs 0.000 claims description 89
150000001413 amino acids Chemical class 0.000 claims description 89
101800004616 Adrenomedullin Proteins 0.000 claims description 76
ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 claims description 76
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 74
102000004379 Adrenomedullin Human genes 0.000 claims description 72
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 70
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 70
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 68
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 62
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 61
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 60
238000000034 method Methods 0.000 claims description 59
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims description 57
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 57
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 54
239000002253 acid Substances 0.000 claims description 52
101000584583 Homo sapiens Receptor activity-modifying protein 1 Proteins 0.000 claims description 50
102100030697 Receptor activity-modifying protein 1 Human genes 0.000 claims description 50
101000584590 Homo sapiens Receptor activity-modifying protein 2 Proteins 0.000 claims description 49
102100030696 Receptor activity-modifying protein 2 Human genes 0.000 claims description 49
239000000203 mixture Substances 0.000 claims description 44
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 43
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 43
238000011282 treatment Methods 0.000 claims description 40
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 38
239000003814 drug Substances 0.000 claims description 37
206010020772 Hypertension Diseases 0.000 claims description 33
125000000539 amino acid group Chemical group 0.000 claims description 32
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 31
235000003704 aspartic acid Nutrition 0.000 claims description 31
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 31
235000013922 glutamic acid Nutrition 0.000 claims description 31
239000004220 glutamic acid Substances 0.000 claims description 31
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 30
235000004279 alanine Nutrition 0.000 claims description 30
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 27
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 27
239000004471 Glycine Substances 0.000 claims description 25
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 25
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 25
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 24
239000004475 Arginine Substances 0.000 claims description 23
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 23
210000004899 c-terminal region Anatomy 0.000 claims description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
229960000310 isoleucine Drugs 0.000 claims description 23
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 23
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 23
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 22
239000008194 pharmaceutical composition Substances 0.000 claims description 22
239000004472 Lysine Substances 0.000 claims description 20
239000000816 peptidomimetic Substances 0.000 claims description 20
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 19
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 19
239000012634 fragment Substances 0.000 claims description 18
230000002265 prevention Effects 0.000 claims description 18
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 17
150000001412 amines Chemical group 0.000 claims description 17
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 17
201000010099 disease Diseases 0.000 claims description 17
235000018977 lysine Nutrition 0.000 claims description 17
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 16
208000019695 Migraine disease Diseases 0.000 claims description 16
206010027599 migraine Diseases 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 15
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 14
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 13
229940102884 adrenalin Drugs 0.000 claims description 12
108010033276 Peptide Fragments Proteins 0.000 claims description 11
102000007079 Peptide Fragments Human genes 0.000 claims description 11
229960002433 cysteine Drugs 0.000 claims description 11
206010019280 Heart failures Diseases 0.000 claims description 10
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 10
206010028980 Neoplasm Diseases 0.000 claims description 10
210000004900 c-terminal fragment Anatomy 0.000 claims description 10
201000011461 pre-eclampsia Diseases 0.000 claims description 10
230000002792 vascular Effects 0.000 claims description 10
206010048554 Endothelial dysfunction Diseases 0.000 claims description 9
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 9
239000004473 Threonine Substances 0.000 claims description 9
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 9
235000018417 cysteine Nutrition 0.000 claims description 9
230000008694 endothelial dysfunction Effects 0.000 claims description 9
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 8
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 8
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 8
125000003277 amino group Chemical group 0.000 claims description 8
210000004898 n-terminal fragment Anatomy 0.000 claims description 8
239000000546 pharmaceutical excipient Substances 0.000 claims description 8
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 8
QWVUOVZJBNQSNS-UHFFFAOYSA-N (+-)-Tropan-3endo,6exo-diol Natural products C1C(O)CC2C(O)CC1N2C QWVUOVZJBNQSNS-UHFFFAOYSA-N 0.000 claims description 7
108060001064 Calcitonin Proteins 0.000 claims description 7
101000690940 Homo sapiens Pro-adrenomedullin Proteins 0.000 claims description 7
241001465754 Metazoa Species 0.000 claims description 7
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
229940044601 receptor agonist Drugs 0.000 claims description 7
239000000018 receptor agonist Substances 0.000 claims description 7
239000004474 valine Substances 0.000 claims description 7
VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical group NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 claims description 6
125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims description 6
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims description 6
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
206010025282 Lymphoedema Diseases 0.000 claims description 6
102000003735 Mesothelin Human genes 0.000 claims description 6
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
230000006378 damage Effects 0.000 claims description 6
102000046663 human ADM Human genes 0.000 claims description 6
208000002502 lymphedema Diseases 0.000 claims description 6
108090000015 Mesothelin Proteins 0.000 claims description 5
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 5
229960004015 calcitonin Drugs 0.000 claims description 5
208000035475 disorder Diseases 0.000 claims description 5
SFVVQRJOGUKCEG-UHFFFAOYSA-N isoechinatine Natural products C1CC(O)C2C(COC(=O)C(O)(C(C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-UHFFFAOYSA-N 0.000 claims description 5
SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 claims description 5
206010027476 Metastases Diseases 0.000 claims description 4
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 4
102100026651 Pro-adrenomedullin Human genes 0.000 claims description 4
206010069351 acute lung injury Diseases 0.000 claims description 4
230000036772 blood pressure Effects 0.000 claims description 4
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 4
230000009401 metastasis Effects 0.000 claims description 4
208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
206010020802 Hypertensive crisis Diseases 0.000 claims description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
208000022873 Ocular disease Diseases 0.000 claims description 3
208000033626 Renal failure acute Diseases 0.000 claims description 3
230000002159 abnormal effect Effects 0.000 claims description 3
201000011040 acute kidney failure Diseases 0.000 claims description 3
230000033115 angiogenesis Effects 0.000 claims description 3
210000004369 blood Anatomy 0.000 claims description 3
239000008280 blood Substances 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
208000020832 chronic kidney disease Diseases 0.000 claims description 3
230000002497 edematous effect Effects 0.000 claims description 3
230000002526 effect on cardiovascular system Effects 0.000 claims description 3
230000008753 endothelial function Effects 0.000 claims description 3
229960001340 histamine Drugs 0.000 claims description 3
229940088597 hormone Drugs 0.000 claims description 3
239000005556 hormone Substances 0.000 claims description 3
208000014674 injury Diseases 0.000 claims description 3
230000000302 ischemic effect Effects 0.000 claims description 3
210000001365 lymphatic vessel Anatomy 0.000 claims description 3
229930182817 methionine Natural products 0.000 claims description 3
230000002093 peripheral effect Effects 0.000 claims description 3
208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
208000031104 Arterial Occlusive disease Diseases 0.000 claims description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
208000032382 Ischaemic stroke Diseases 0.000 claims description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
208000027418 Wounds and injury Diseases 0.000 claims description 2
208000008445 altitude sickness Diseases 0.000 claims description 2
208000029078 coronary artery disease Diseases 0.000 claims description 2
208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
208000015658 resistant hypertension Diseases 0.000 claims description 2
230000000699 topical effect Effects 0.000 claims description 2
230000008733 trauma Effects 0.000 claims description 2
PMLJIHNCYNOQEQ-REOHCLBHSA-N L-aspartic 1-amide Chemical compound NC(=O)[C@@H](N)CC(O)=O PMLJIHNCYNOQEQ-REOHCLBHSA-N 0.000 claims 4
229960002743 glutamine Drugs 0.000 claims 4
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims 4
229910021653 sulphate ion Inorganic materials 0.000 claims 4
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 3
229940025084 amphetamine Drugs 0.000 claims 3
102100038518 Calcitonin Human genes 0.000 claims 2
208000010285 Ventilator-Induced Lung Injury Diseases 0.000 claims 2
230000001919 adrenal effect Effects 0.000 claims 2
150000001510 aspartic acids Chemical class 0.000 claims 2
150000002411 histidines Chemical class 0.000 claims 2
230000008929 regeneration Effects 0.000 claims 2
238000011069 regeneration method Methods 0.000 claims 2
229940063675 spermine Drugs 0.000 claims 2
APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 claims 2
101000576802 Homo sapiens Mesothelin Proteins 0.000 claims 1
206010052428 Wound Diseases 0.000 claims 1
150000001483 arginine derivatives Chemical class 0.000 claims 1
230000007850 degeneration Effects 0.000 claims 1
230000001605 fetal effect Effects 0.000 claims 1
208000027866 inflammatory disease Diseases 0.000 claims 1
230000005980 lung dysfunction Effects 0.000 claims 1
230000003169 placental effect Effects 0.000 claims 1
BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical group OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims 1
230000006492 vascular dysfunction Effects 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 55
239000003446 ligand Substances 0.000 abstract description 44
102100024654 Calcitonin gene-related peptide type 1 receptor Human genes 0.000 description 188
101710118454 Calcitonin gene-related peptide type 1 receptor Proteins 0.000 description 188
102000004196 processed proteins & peptides Human genes 0.000 description 181
102000005962 receptors Human genes 0.000 description 163
108020003175 receptors Proteins 0.000 description 163
229920001184 polypeptide Polymers 0.000 description 124
150000001875 compounds Chemical class 0.000 description 116
108010064300 Receptor Activity-Modifying Proteins Proteins 0.000 description 79
102000015146 Receptor Activity-Modifying Proteins Human genes 0.000 description 79
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 55
101150011411 imd gene Proteins 0.000 description 45
125000003275 alpha amino acid group Chemical group 0.000 description 33
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 30
150000002632 lipids Chemical class 0.000 description 30
230000004048 modification Effects 0.000 description 29
238000012986 modification Methods 0.000 description 29
229920001223 polyethylene glycol Polymers 0.000 description 29
102000009027 Albumins Human genes 0.000 description 24
108010088751 Albumins Proteins 0.000 description 24
241000282414 Homo sapiens Species 0.000 description 24
230000037396 body weight Effects 0.000 description 23
210000004027 cell Anatomy 0.000 description 23
230000036515 potency Effects 0.000 description 23
229940079593 drug Drugs 0.000 description 22
238000009472 formulation Methods 0.000 description 22
238000006467 substitution reaction Methods 0.000 description 21
239000000126 substance Substances 0.000 description 19
230000004071 biological effect Effects 0.000 description 17
230000004913 activation Effects 0.000 description 16
229940002612 prodrug Drugs 0.000 description 16
239000000651 prodrug Substances 0.000 description 16
238000005576 amination reaction Methods 0.000 description 15
239000000725 suspension Substances 0.000 description 15
101000584593 Homo sapiens Receptor activity-modifying protein 3 Proteins 0.000 description 14
206010030113 Oedema Diseases 0.000 description 14
102100030711 Receptor activity-modifying protein 3 Human genes 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 14
238000001727 in vivo Methods 0.000 description 13
230000001965 increasing effect Effects 0.000 description 13
229920000642 polymer Polymers 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
150000008574 D-amino acids Chemical class 0.000 description 12
239000002202 Polyethylene glycol Substances 0.000 description 12
230000001154 acute effect Effects 0.000 description 12
238000003556 assay Methods 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 12
235000018102 proteins Nutrition 0.000 description 12
230000011664 signaling Effects 0.000 description 12
206010019233 Headaches Diseases 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
108010050923 calcitonin gene-related peptide (8-37) Proteins 0.000 description 11
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 11
108091006116 chimeric peptides Proteins 0.000 description 11
238000007069 methylation reaction Methods 0.000 description 11
230000004083 survival effect Effects 0.000 description 11
208000024891 symptom Diseases 0.000 description 11
NDACAFBDTQIYCQ-YVQXRMNASA-N val(8)-phe(37)-cgrp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C1=CN=CN1 NDACAFBDTQIYCQ-YVQXRMNASA-N 0.000 description 11
230000021736 acetylation Effects 0.000 description 10
238000006640 acetylation reaction Methods 0.000 description 10
150000001408 amides Chemical group 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
238000002360 preparation method Methods 0.000 description 10
238000003786 synthesis reaction Methods 0.000 description 10
238000012360 testing method Methods 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 9
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 9
102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 9
101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 9
239000004480 active ingredient Substances 0.000 description 9
210000003169 central nervous system Anatomy 0.000 description 9
231100000869 headache Toxicity 0.000 description 9
230000000144 pharmacologic effect Effects 0.000 description 9
229940044551 receptor antagonist Drugs 0.000 description 9
239000002464 receptor antagonist Substances 0.000 description 9
230000004936 stimulating effect Effects 0.000 description 9
229940124597 therapeutic agent Drugs 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
208000002296 eclampsia Diseases 0.000 description 8
210000002889 endothelial cell Anatomy 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
108091005601 modified peptides Proteins 0.000 description 8
208000010125 myocardial infarction Diseases 0.000 description 8
230000035755 proliferation Effects 0.000 description 8
241000282412 Homo Species 0.000 description 7
229920001612 Hydroxyethyl starch Polymers 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
230000001684 chronic effect Effects 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
206010012601 diabetes mellitus Diseases 0.000 description 7
229940050526 hydroxyethylstarch Drugs 0.000 description 7
210000005073 lymphatic endothelial cell Anatomy 0.000 description 7
230000002503 metabolic effect Effects 0.000 description 7
230000003389 potentiating effect Effects 0.000 description 7
201000001474 proteinuria Diseases 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000011191 terminal modification Methods 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 6
208000002193 Pain Diseases 0.000 description 6
208000006011 Stroke Diseases 0.000 description 6
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
206010064930 age-related macular degeneration Diseases 0.000 description 6
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
238000011161 development Methods 0.000 description 6
239000012091 fetal bovine serum Substances 0.000 description 6
208000002780 macular degeneration Diseases 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
230000026792 palmitoylation Effects 0.000 description 6
238000010647 peptide synthesis reaction Methods 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
230000017854 proteolysis Effects 0.000 description 6
208000002815 pulmonary hypertension Diseases 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
239000011593 sulfur Substances 0.000 description 6
229910052717 sulfur Inorganic materials 0.000 description 6
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
150000008575 L-amino acids Chemical class 0.000 description 5
206010036790 Productive cough Diseases 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
239000000562 conjugate Substances 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
206010015037 epilepsy Diseases 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 5
238000001802 infusion Methods 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
125000005647 linker group Chemical group 0.000 description 5
230000029226 lipidation Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
208000031225 myocardial ischemia Diseases 0.000 description 5
231100000252 nontoxic Toxicity 0.000 description 5
230000003000 nontoxic effect Effects 0.000 description 5
239000002674 ointment Substances 0.000 description 5
230000036407 pain Effects 0.000 description 5
239000000813 peptide hormone Substances 0.000 description 5
230000035935 pregnancy Effects 0.000 description 5
150000003384 small molecules Chemical class 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
208000024794 sputum Diseases 0.000 description 5
210000003802 sputum Anatomy 0.000 description 5
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 4
201000001320 Atherosclerosis Diseases 0.000 description 4
102000055006 Calcitonin Human genes 0.000 description 4
102000014914 Carrier Proteins Human genes 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
108091006905 Human Serum Albumin Proteins 0.000 description 4
102000008100 Human Serum Albumin Human genes 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
238000000719 MTS assay Methods 0.000 description 4
231100000070 MTS assay Toxicity 0.000 description 4
229940122985 Peptide agonist Drugs 0.000 description 4
206010037423 Pulmonary oedema Diseases 0.000 description 4
206010047163 Vasospasm Diseases 0.000 description 4
230000010933 acylation Effects 0.000 description 4
238000005917 acylation reaction Methods 0.000 description 4
125000004429 atom Chemical group 0.000 description 4
108091008324 binding proteins Proteins 0.000 description 4
239000011575 calcium Substances 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
239000002934 diuretic Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
239000002502 liposome Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
201000005857 malignant hypertension Diseases 0.000 description 4
230000000873 masking effect Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
239000002245 particle Substances 0.000 description 4
230000004962 physiological condition Effects 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
239000013641 positive control Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000004224 protection Effects 0.000 description 4
208000005333 pulmonary edema Diseases 0.000 description 4
230000002685 pulmonary effect Effects 0.000 description 4
230000002285 radioactive effect Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
230000001953 sensory effect Effects 0.000 description 4
239000002904 solvent Substances 0.000 description 4
125000006850 spacer group Chemical group 0.000 description 4
241000894007 species Species 0.000 description 4
239000007921 spray Substances 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
230000029663 wound healing Effects 0.000 description 4
XQPYRJIMPDBGRW-UHFFFAOYSA-N 2-[2-[2-(9h-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]acetic acid Chemical compound C1=CC=C2C(COC(=O)NCCOCCOCC(=O)O)C3=CC=CC=C3C2=C1 XQPYRJIMPDBGRW-UHFFFAOYSA-N 0.000 description 3
208000028185 Angioedema Diseases 0.000 description 3
206010007556 Cardiac failure acute Diseases 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
206010056340 Diabetic ulcer Diseases 0.000 description 3
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
108091006027 G proteins Proteins 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 3
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
102000003729 Neprilysin Human genes 0.000 description 3
108090000028 Neprilysin Proteins 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
206010064911 Pulmonary arterial hypertension Diseases 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
238000010171 animal model Methods 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
239000002585 base Substances 0.000 description 3
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
206010006475 bronchopulmonary dysplasia Diseases 0.000 description 3
239000000872 buffer Substances 0.000 description 3
150000003857 carboxamides Chemical class 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
229940109239 creatinine Drugs 0.000 description 3
125000004122 cyclic group Chemical group 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
230000001882 diuretic effect Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
210000003038 endothelium Anatomy 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
230000005714 functional activity Effects 0.000 description 3
230000004927 fusion Effects 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
229910000040 hydrogen fluoride Inorganic materials 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
208000028867 ischemia Diseases 0.000 description 3
230000000155 isotopic effect Effects 0.000 description 3
208000017169 kidney disease Diseases 0.000 description 3
239000008101 lactose Substances 0.000 description 3
230000001926 lymphatic effect Effects 0.000 description 3
239000008176 lyophilized powder Substances 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000002107 myocardial effect Effects 0.000 description 3
CGDZXLJGHVKVIE-DNVCBOLYSA-N n-[(3r,6s)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide Chemical compound FC1=CC=CC([C@H]2CN(CC(F)(F)F)C(=O)[C@H](NC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)=C1F CGDZXLJGHVKVIE-DNVCBOLYSA-N 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
230000003204 osmotic effect Effects 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
230000035488 systolic blood pressure Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
230000024883 vasodilation Effects 0.000 description 3
IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 2
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
239000005541 ACE inhibitor Substances 0.000 description 2
235000019489 Almond oil Nutrition 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
206010003210 Arteriosclerosis Diseases 0.000 description 2
208000003174 Brain Neoplasms Diseases 0.000 description 2
101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
229940127597 CGRP antagonist Drugs 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
102100035418 Ceramide synthase 4 Human genes 0.000 description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
208000006561 Cluster Headache Diseases 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical group CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
208000007342 Diabetic Nephropathies Diseases 0.000 description 2
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108010087819 Fc receptors Proteins 0.000 description 2
102000009109 Fc receptors Human genes 0.000 description 2
102000030782 GTP binding Human genes 0.000 description 2
108091000058 GTP-Binding Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229920002148 Gellan gum Polymers 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
206010018713 Gravitational oedema Diseases 0.000 description 2
101000737544 Homo sapiens Ceramide synthase 4 Proteins 0.000 description 2
101000780028 Homo sapiens Natriuretic peptides A Proteins 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
208000004852 Lung Injury Diseases 0.000 description 2
208000019693 Lung disease Diseases 0.000 description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
206010049567 Miller Fisher syndrome Diseases 0.000 description 2
208000034486 Multi-organ failure Diseases 0.000 description 2
208000010718 Multiple Organ Failure Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010065673 Nephritic syndrome Diseases 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
241001494479 Pecora Species 0.000 description 2
229940083963 Peptide antagonist Drugs 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
102000001938 Plasminogen Activators Human genes 0.000 description 2
108010001014 Plasminogen Activators Proteins 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
206010035669 Pneumonia aspiration Diseases 0.000 description 2
229920001710 Polyorthoester Polymers 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
OATSQCXMYKYFQO-UHFFFAOYSA-N S-methyl thioacetate Chemical compound CSC(C)=O OATSQCXMYKYFQO-UHFFFAOYSA-N 0.000 description 2
201000004239 Secondary hypertension Diseases 0.000 description 2
108010086019 Secretin Proteins 0.000 description 2
102100037505 Secretin Human genes 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
241000282887 Suidae Species 0.000 description 2
239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 2
102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
208000007587 Transfusion-Related Acute Lung Injury Diseases 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
235000010358 acesulfame potassium Nutrition 0.000 description 2
239000000619 acesulfame-K Substances 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
229940050528 albumin Drugs 0.000 description 2
239000008168 almond oil Substances 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
229960002684 aminocaproic acid Drugs 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
230000019552 anatomical structure morphogenesis Effects 0.000 description 2
239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
229940127282 angiotensin receptor antagonist Drugs 0.000 description 2
229940125364 angiotensin receptor blocker Drugs 0.000 description 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
239000008135 aqueous vehicle Substances 0.000 description 2
201000009807 aspiration pneumonia Diseases 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000007640 basal medium Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
150000001576 beta-amino acids Chemical class 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000036983 biotransformation Effects 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 2
108010029577 calcitonin gene-related peptide (28-37) Proteins 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
230000003293 cardioprotective effect Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
230000001886 ciliary effect Effects 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
208000018912 cluster headache syndrome Diseases 0.000 description 2
230000004186 co-expression Effects 0.000 description 2
238000004891 communication Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
208000002925 dental caries Diseases 0.000 description 2
238000001514 detection method Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
208000033679 diabetic kidney disease Diseases 0.000 description 2
230000035487 diastolic blood pressure Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
150000002019 disulfides Chemical class 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000006196 drop Substances 0.000 description 2
238000009510 drug design Methods 0.000 description 2
206010014599 encephalitis Diseases 0.000 description 2
239000006274 endogenous ligand Substances 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
230000007247 enzymatic mechanism Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
229940093471 ethyl oleate Drugs 0.000 description 2
230000029142 excretion Effects 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000000216 gellan gum Substances 0.000 description 2
235000010492 gellan gum Nutrition 0.000 description 2
229960001031 glucose Drugs 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000010651 grapefruit oil Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
102000056614 human NPPA Human genes 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
229920001477 hydrophilic polymer Polymers 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
230000001631 hypertensive effect Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000007574 infarction Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
230000003870 intestinal permeability Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
208000037906 ischaemic injury Diseases 0.000 description 2
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
125000005956 isoquinolyl group Chemical group 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
239000006193 liquid solution Substances 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
229960001855 mannitol Drugs 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
229960003105 metformin Drugs 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
235000013923 monosodium glutamate Nutrition 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229940100656 nasal solution Drugs 0.000 description 2
208000004296 neuralgia Diseases 0.000 description 2
230000001272 neurogenic effect Effects 0.000 description 2
208000021722 neuropathic pain Diseases 0.000 description 2
230000004112 neuroprotection Effects 0.000 description 2
239000012038 nucleophile Substances 0.000 description 2
ITIXDWVDFFXNEG-JHOUSYSJSA-N olcegepant Chemical compound C([C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCN(CC1)C=1C=CN=CC=1)NC(=O)N1CCC(CC1)N1C(NC2=CC=CC=C2C1)=O)C1=CC(Br)=C(O)C(Br)=C1 ITIXDWVDFFXNEG-JHOUSYSJSA-N 0.000 description 2
239000002997 ophthalmic solution Substances 0.000 description 2
229940054534 ophthalmic solution Drugs 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
150000002923 oximes Chemical class 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000006179 pH buffering agent Substances 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000004963 pathophysiological condition Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000006320 pegylation Effects 0.000 description 2
210000001428 peripheral nervous system Anatomy 0.000 description 2
230000006461 physiological response Effects 0.000 description 2
229940127126 plasminogen activator Drugs 0.000 description 2
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
239000004626 polylactic acid Substances 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
238000011002 quantification Methods 0.000 description 2
206010061928 radiculitis Diseases 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
102220080600 rs797046116 Human genes 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
229960004017 salmeterol Drugs 0.000 description 2
229960002101 secretin Drugs 0.000 description 2
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 2
230000028327 secretion Effects 0.000 description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
230000008054 signal transmission Effects 0.000 description 2
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
229940073490 sodium glutamate Drugs 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000003549 soybean oil Substances 0.000 description 2
235000012424 soybean oil Nutrition 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
229950002563 telcagepant Drugs 0.000 description 2
RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 description 1
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
ZGIBSKHPEMBBCT-UHFFFAOYSA-N 2-acetamidooxybenzoic acid Chemical compound CC(=O)NOC1=CC=CC=C1C(O)=O ZGIBSKHPEMBBCT-UHFFFAOYSA-N 0.000 description 1
OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 description 1
ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 1
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
241000186361 Actinobacteria <class> Species 0.000 description 1
206010001014 Acute polyneuropathies Diseases 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
102000003916 Arrestin Human genes 0.000 description 1
108090000328 Arrestin Proteins 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
101800001288 Atrial natriuretic factor Proteins 0.000 description 1
102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
239000002083 C09CA01 - Losartan Substances 0.000 description 1
239000004072 C09CA03 - Valsartan Substances 0.000 description 1
239000002053 C09CA06 - Candesartan Substances 0.000 description 1
239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
206010058019 Cancer Pain Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
206010007572 Cardiac hypertrophy Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
208000004990 Cardiorenal syndrome Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
102000009660 Cholinergic Receptors Human genes 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010010969 Cor pulmonale acute Diseases 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
206010058202 Cystoid macular oedema Diseases 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
206010011985 Decubitus ulcer Diseases 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
206010063547 Diabetic macroangiopathy Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
102000005593 Endopeptidases Human genes 0.000 description 1
108010059378 Endopeptidases Proteins 0.000 description 1
102000002045 Endothelin Human genes 0.000 description 1
108050009340 Endothelin Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000034286 G proteins Human genes 0.000 description 1
102000005915 GABA Receptors Human genes 0.000 description 1
108010005551 GABA Receptors Proteins 0.000 description 1
229940125633 GPCR agonist Drugs 0.000 description 1
108010016122 Ghrelin Receptors Proteins 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
206010059484 Haemodilution Diseases 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000032456 Hemorrhagic Shock Diseases 0.000 description 1
206010019670 Hepatic function abnormal Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
201000002980 Hyperparathyroidism Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
241000283953 Lagomorpha Species 0.000 description 1
VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 1
108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000032912 Local swelling Diseases 0.000 description 1
102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
208000001344 Macular Edema Diseases 0.000 description 1
206010025421 Macule Diseases 0.000 description 1
108010008364 Melanocortins Proteins 0.000 description 1
239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
206010027202 Meningitis bacterial Diseases 0.000 description 1
206010027260 Meningitis viral Diseases 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
102400000108 N-terminal peptide Human genes 0.000 description 1
101800000597 N-terminal peptide Proteins 0.000 description 1
108020001621 Natriuretic Peptide Proteins 0.000 description 1
102000004571 Natriuretic peptide Human genes 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010029240 Neuritis Diseases 0.000 description 1
102000003797 Neuropeptides Human genes 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010030043 Ocular hypertension Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010043958 Peptoids Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
206010036105 Polyneuropathy Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
206010037779 Radiculopathy Diseases 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
201000003099 Renovascular Hypertension Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
208000021063 Respiratory fume inhalation disease Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038886 Retinal oedema Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
102100040756 Rhodopsin Human genes 0.000 description 1
108090000820 Rhodopsin Proteins 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
241000589970 Spirochaetales Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
102000007451 Steroid Receptors Human genes 0.000 description 1
108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
206010042682 Swelling face Diseases 0.000 description 1
206010042957 Systolic hypertension Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
206010044541 Traumatic shock Diseases 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
108010001957 Ularitide Proteins 0.000 description 1
102400001279 Urodilatin Human genes 0.000 description 1
SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
206010056091 Varices oesophageal Diseases 0.000 description 1
206010046996 Varicose vein Diseases 0.000 description 1
208000032594 Vascular Remodeling Diseases 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000000397 acetylating effect Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
201000006303 acute cor pulmonale Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229940083712 aldosterone antagonist Drugs 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
102000004139 alpha-Amylases Human genes 0.000 description 1
108090000637 alpha-Amylases Proteins 0.000 description 1
229940024171 alpha-amylase Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229920005603 alternating copolymer Polymers 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000003708 ampul Substances 0.000 description 1
RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
229960002105 amrinone Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000002460 anti-migrenic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000002567 autonomic effect Effects 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
201000009904 bacterial meningitis Diseases 0.000 description 1
159000000009 barium salts Chemical class 0.000 description 1
229960004530 benazepril Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
125000003310 benzodiazepinyl group Chemical group N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000008512 biological response Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
210000000746 body region Anatomy 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
230000037182 bone density Effects 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
229960000932 candesartan Drugs 0.000 description 1
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
238000005878 carbamate elimination reaction Methods 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
150000007942 carboxylates Chemical group 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
229940045200 cardioprotective agent Drugs 0.000 description 1
239000012659 cardioprotective agent Substances 0.000 description 1
230000003177 cardiotonic effect Effects 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
229950008486 carperitide Drugs 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000002701 cell growth assay Methods 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
229940106681 chloroacetic acid Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
208000033630 chronic polyneuropathy Diseases 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
229960005025 cilazapril Drugs 0.000 description 1
RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
229960004588 cilostazol Drugs 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
230000005796 circulatory shock Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229960001117 clenbuterol Drugs 0.000 description 1
STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
230000004154 complement system Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011340 continuous therapy Methods 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
108091008723 corticosteroid receptors Proteins 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
230000001517 counterregulatory effect Effects 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
ILRYLPWNYFXEMH-UHFFFAOYSA-N cystathionine Chemical compound OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
229940097265 cysteamine hydrochloride Drugs 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
201000010206 cystoid macular edema Diseases 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229960001145 deflazacort Drugs 0.000 description 1
FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000021045 dietary change Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
239000000428 dust Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
229950006127 embusartan Drugs 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
230000008497 endothelial barrier function Effects 0.000 description 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940100321 entresto Drugs 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
208000024170 esophageal varices Diseases 0.000 description 1
201000010120 esophageal varix Diseases 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
239000006277 exogenous ligand Substances 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
210000000416 exudates and transudate Anatomy 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
210000002468 fat body Anatomy 0.000 description 1
229960001022 fenoterol Drugs 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
229960003973 fluocortolone Drugs 0.000 description 1
GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
229960002848 formoterol Drugs 0.000 description 1
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
229960002490 fosinopril Drugs 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
238000009650 gentamicin protection assay Methods 0.000 description 1
229940124750 glucocorticoid receptor agonist Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229940049906 glutamate Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
150000002357 guanidines Chemical class 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
231100000334 hepatotoxic Toxicity 0.000 description 1
230000003082 hepatotoxic effect Effects 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical group CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
ZASXKEGREHRXDL-CAWNUZPDSA-H hexasodium;4-[[(2s,4r)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1 ZASXKEGREHRXDL-CAWNUZPDSA-H 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
150000002410 histidine derivatives Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
208000015210 hypertensive heart disease Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
239000012216 imaging agent Substances 0.000 description 1
229960001195 imidapril Drugs 0.000 description 1
KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
201000006334 interstitial nephritis Diseases 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000002083 iodinating effect Effects 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
208000012947 ischemia reperfusion injury Diseases 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
108010057821 leucylproline Proteins 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
108010047498 long-chain carboxylesterase Proteins 0.000 description 1
229960004773 losartan Drugs 0.000 description 1
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
LYVGOAYMIAQLHI-UHFFFAOYSA-N methyl 2-butyl-1-[[2-fluoro-4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-6-oxopyridine-4-carboxylate Chemical compound CCCCC1=CC(C(=O)OC)=CC(=O)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1F LYVGOAYMIAQLHI-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
206010062198 microangiopathy Diseases 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
229960003574 milrinone Drugs 0.000 description 1
239000002395 mineralocorticoid Substances 0.000 description 1
239000002394 mineralocorticoid antagonist Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960005170 moexipril Drugs 0.000 description 1
QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 description 1
QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
230000003680 myocardial damage Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000000692 natriuretic peptide Substances 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000007830 nerve conduction Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
229960001267 nesiritide Drugs 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
230000003040 nociceptive effect Effects 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
229950006377 olcegepant Drugs 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
229940069265 ophthalmic ointment Drugs 0.000 description 1
229940100654 ophthalmic suspension Drugs 0.000 description 1
238000005457 optimization Methods 0.000 description 1
239000000082 organ preservation Substances 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
239000000863 peptide conjugate Substances 0.000 description 1
229960002582 perindopril Drugs 0.000 description 1
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000036513 peripheral conductance Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
206010034754 petechiae Diseases 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
PETXWIMJICIQTQ-UHFFFAOYSA-N phenylmethoxymethanol Chemical group OCOCC1=CC=CC=C1 PETXWIMJICIQTQ-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229960002164 pimobendan Drugs 0.000 description 1
GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 1
229960005414 pirbuterol Drugs 0.000 description 1
230000010118 platelet activation Effects 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
239000002745 poly(ortho ester) Substances 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
208000019629 polyneuritis Diseases 0.000 description 1
208000006473 polyradiculopathy Diseases 0.000 description 1
208000007232 portal hypertension Diseases 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960001917 prednylidene Drugs 0.000 description 1
WSVOMANDJDYYEY-CWNVBEKCSA-N prednylidene Chemical group O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WSVOMANDJDYYEY-CWNVBEKCSA-N 0.000 description 1
210000003814 preoptic area Anatomy 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
201000008312 primary pulmonary hypertension Diseases 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002947 procoagulating effect Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
108010000947 protamine zinc Chemical class 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
229960001455 quinapril Drugs 0.000 description 1
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000001084 renoprotective effect Effects 0.000 description 1
230000001846 repelling effect Effects 0.000 description 1
229960002720 reproterol Drugs 0.000 description 1
WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000020874 response to hypoxia Effects 0.000 description 1
230000008458 response to injury Effects 0.000 description 1
230000000250 revascularization Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000006798 ring closing metathesis reaction Methods 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000007017 scission Effects 0.000 description 1
208000011571 secondary malignant neoplasm Diseases 0.000 description 1
208000037812 secondary pulmonary hypertension Diseases 0.000 description 1
VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229960003310 sildenafil Drugs 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
108010064556 somatostatin receptor subtype-4 Proteins 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
229960002909 spirapril Drugs 0.000 description 1
HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
108700035424 spirapril Proteins 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000002311 subsequent effect Effects 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
150000003463 sulfur Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960000835 tadalafil Drugs 0.000 description 1
IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229960005187 telmisartan Drugs 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
210000001103 thalamus Anatomy 0.000 description 1
229940124598 therapeutic candidate Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
230000025366 tissue development Effects 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
229960005461 torasemide Drugs 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
229960000859 tulobuterol Drugs 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
210000004981 tumor-associated macrophage Anatomy 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
IUCCYQIEZNQWRS-DWWHXVEHSA-N ularitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 IUCCYQIEZNQWRS-DWWHXVEHSA-N 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
229940005605 valeric acid Drugs 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960004699 valsartan Drugs 0.000 description 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
229960002381 vardenafil Drugs 0.000 description 1
208000027185 varicose disease Diseases 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
230000004218 vascular function Effects 0.000 description 1
230000006442 vascular tone Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
230000002666 vasoprotective effect Effects 0.000 description 1
230000002455 vasospastic effect Effects 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
201000010044 viral meningitis Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000036266 weeks of gestation Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1